Abstract
The tyrphostin 4-(3-chloroanilino)-6,7-dimethoxyquinazoline (AG1478) is undergoing evaluation as a potential new anticancer agent. We have developed a specific and sensitive reversed-phase HPLC assay for AG1478 in mouse plasma. The method involves a rapid and simple extraction process followed by separation on a Symmetry C8 stationary phase with a gradient of acetonitrile in ammonium acetate buffer. A linear response was achieved over the concentration range of 0.2-100 μM using multilevel calibration with internal standard method of calculation. Inter- and intra-assay accuracy and precision were better than ±10%. The limit of quantitation was 0.2 μM. We have used this method to study the preclinical pharmacokinetics of this new agent in mice.
| Original language | English |
|---|---|
| Pages (from-to) | 193-199 |
| Number of pages | 7 |
| Journal | Journal of Chromatography B: Biomedical Sciences and Applications |
| Volume | 754 |
| Issue number | 1 |
| DOIs | |
| State | Published - 15 Apr 2001 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- AG1478
- Tyrphostins
Fingerprint
Dive into the research topics of 'High-performance liquid chromatographic analysis of the tyrphostin AG1478, a specific inhibitor of the epidermal growth factor receptor tyrosine kinase, in mouse plasma'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver